Alicia Morgans, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Novartis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Advanced Accelerator Applications
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Myovant
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    BMS
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Dendreon
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Clovis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Telix
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2022

Pages

Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)